Mr. Brohman co-founded NX Prenatal with a goal of helping families achieve healthy birth outcomes, with inspiration from his son who was born with special needs. His 30+ year career in the biotech space started as a licensing and acquisition specialist for the cardiology device pioneers Cordis and Johnson & Johnson. Since then, he has co-founded firms commercializing precision medicine products in the pharma, imaging agent, and diagnostics fields. While at NX Prenatal, he has driven the development of the worlds most extensive patent portfolio in exosome-based liquid biopsy for maternal-fetal medicine applications, and has also led the companys partnering activities with the NICHD and Thermo Fisher Scientific.
Women's Health Showcase:
NX Prenatal utilizes proprietary exosome-based liquid biopsy techniques to create breakthroughs in maternal-fetal diagnostics. Our NeXosome® Platform has yielded Preterm Birth and Preeclampsia biomarker panels at week 10-12 of pregnancy in asymptomatic women to support personalized care pathways.
Exosomes: Decoding Maternal-Fetal Cross Talk
Maternal-fetal cross-talk is mediated by exosomes, which actively support a number of physiological systems, including regulating the immune protection of the fetus. NX Prenatal has demonstrated that the profiling of exosomal-bound proteins circulating in pregnant women provides early markers predicting preterm birth and preeclampsia, and also provides new insight into the molecular pathways associated with such outcomes.
Aleksandar Rajkovic, UCSF
Researchers have long been recognizing the uniqueness of women’s health and its substantial effect on clinical practice, acknowledging the increasing appreciation of the importance of multidisciplinary approaches to health and disease. In every organ system, there are diseases that are unique to women, more common in women than in men, or characterized by differences in disease course in women compared to men. This Track will focus on the following topics related to Women’s Health: